RECIST Version 1.1

The new version of RECIST (version 1.1) has been presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland (21-24 October 2008) and will be published in a special edition of the European Journal of Cancer in the first quarter of 2009.

Presentation available here

RECIST Version 1.0

RECIST Article | RECIST Form | RECIST Follow-up Form

Questions & Answers

• Q1:Which axis to take into account to measure the longest diameter? (April 2000)
• Q2: How to measure irregular shaped tumor? (April 2000)
• Q3: Target lesions not followed with the same technique, what to do? (September 2000)
• Q4: Combination of uni and bidimensional disease, is it possible? (November 2000)
• Q5: Maximum diameter at follow up? (November 2000)
• Q6: Mammography to assess breast cancer is it allowed? (April 2000)
• Q7: Non target lesion not followed: impact on OR. (August 1999)
• Q8: Unconfirmed PR/CR are SD or PD? (August 1999)
• Q9: Missing measurements (see also Q3 and Q7). (December 1999)
• Q10: Number of target lesions to be selected? (October 1999)
• Q11: Number of target lesions to assess if response is a secondary endpoint (see also Q10)? (July 2000)
• Q12: CA125 and ovarian tumor response to chemotherapy? (
• Q13: How to combined the results of two subsequent evaluations to define the best overall response? (June 2000)
• Q14: Target lesions becoming non measurable what to do? (September 2000)
• Q15: Minimum size of lesions according to CT scan slice thickness? (September 2000)
• Q16: Time points to measure duration of response. (September 2000)
• Q17: Are RECIST criteria accepted by regulatory agencies? (October 2000)
• Q18: In the Reporting of Results sections it mentions the nine categories of response but number 8 is missing from the list? (December 2000)
• Q19: The definition of progression depends on the status of all target lesions or only of one of them? (January 2001)
• Q20: How to measure one lesion split in two lesions? (May 2001)
• Q 21: Progression in non-target lesions: one lesion Vs all lesions? How to assess this? (June 2001)
• Q22: Progression with appearance of new lesion: minimum size of new lesion? (October 2001)
• Q23: Incoherence in the text of the publication: appearance of new lesion (November 2001)
• Q 24: How do we proceed if several unique lesions at baseline become confluent at a follow-up evaluation? (March 2003)

Please address here your question related to the implementation of RECIST
The question will be automatically re-directed to the members of the RECIST working party

PRINTABLE VERSION